A2AR eGFP reporter mouse enables elucidation of A2AR expression dynamics during anti-tumor immune responses
Open Access
- 1 November 2023
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-15
Abstract
There is significant clinical interest in targeting adenosine-mediated immunosuppression, with several small molecule inhibitors having been developed for targeting the A2AR receptor. Understanding of the mechanism by which A2AR is regulated has been hindered by difficulty in identifying the cell types that express A2AR due to a lack of robust antibodies for these receptors. To overcome this limitation, here an A2AR eGFP reporter mouse is developed, enabling the expression of A2AR during ongoing anti-tumor immune responses to be assessed. This reveals that A2AR is highly expressed on all tumor-infiltrating lymphocyte subsets including Natural Killer (NK) cells, NKT cells, γδ T cells, conventional CD4+ and CD8+ T lymphocytes and on a MHCIIhiCD86hi subset of type 2 conventional dendritic cells. In response to PD-L1 blockade, the emergence of PD-1+A2AR- cells correlates with successful therapeutic responses, whilst IL-18 is identified as a cytokine that potently upregulates A2AR and synergizes with A2AR deficiency to improve anti-tumor immunity. These studies provide insight into the biology of A2AR in the context of anti-tumor immunity and reveals potential combination immunotherapy approaches.Keywords
Funding Information
- Victorian Cancer Agency (MCRF20011)
- National Breast Cancer Foundation (ECF-17-005)
This publication has 60 references indexed in Scilit:
- RNA-SeQC: RNA-seq metrics for quality control and process optimizationBioinformatics, 2012
- Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variationNucleic Acids Research, 2012
- Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptorCancer Immunology, Immunotherapy, 2011
- CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune SuppressionCancer Research, 2010
- The A2aR adenosine receptor controls cytokine production in iNKT cellsEuropean Journal of Immunology, 2010
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- Adenosine receptors in regulation of dendritic cell differentiation and functionBlood, 2008
- Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppressionJournal of Experimental Medicine, 2007
- A2A adenosine receptor protects tumors from antitumor T cellsProceedings of the National Academy of Sciences of the United States of America, 2006
- Clinical and Biological Effects of Recombinant Human Interleukin-18 Administered by Intravenous Infusion to Patients with Advanced CancerClinical Cancer Research, 2006